No trading implications from this filing — it reflects a routine governance adjustment with no change in board composition or leadership. Monitor upcoming proxy filings for any additional board changes or governance updates.
Price Chart
Executive Summary
Sana Biotechnology reclassified director Steven D. Harr, M.D. from a Class I to a Class III director to balance board class composition in accordance with its charter. The move was administrative, with no interruption in service, and the board now has three directors in each class.
Key Facts
- Steven D. Harr, M.D. resigned as a Class I director and was immediately reappointed as a Class III director.
- The reclassification was made to achieve equal balance among the three board classes per the company's Certificate of Incorporation.
- Dr. Harr's board service is deemed to have continued uninterrupted.
- The board now consists of three directors in each of Class I, II, and III.
Financial Impact
No financial impact — this was an administrative board reclassification.
Risk Factors
- None identified — this was a procedural board rebalancing with no executive departure or governance controversy.
- Minimal investor relations risk given the clear explanation and continuity of service.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-174531 |
| Document: 0001193125-26-174531-index-headers.html | 0001193125-26-174531 |
| Document: 0001193125-26-174531-index.html | 0001193125-26-174531 |
| Document: 0001193125-26-174531.txt | 0001193125-26-174531 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $3.79 $3.17 | ▼ −16.36% | ▼ −15.30% | $2.87 (−24.41%) |
Aug 10, 2026 7w ago | Press Release | $3.79 $3.17 | ▼ −16.36% | ▼ −15.30% | $2.87 (−24.41%) |
May 11, 2026 20w ago | 8-K | $3.26 $2.82 | ▼ −13.50% | ▼ −11.77% | $2.87 (−12.12%) |
May 11, 2026 20w ago | Press Release | $3.26 $2.82 | ▲ +13.50% | ▲ +11.77% | $2.87 (+12.12%) |
Apr 24, 2026 23w ago | DEFA14A | $3.29 $3.15 | ▼ −4.26% | ▼ −8.28% | $2.87 (−12.92%) |
Apr 24, 2026 23w ago | 8-K | $3.29 $3.15 | ▼ −4.26% | ▼ −8.28% | $2.87 (−12.92%) |
Apr 13, 2026 24w ago | 8-K | $3.48 $3.56 | ▲ +2.30% | ▼ −4.00% | $2.87 (−17.67%) |
Apr 13, 2026 24w ago | Press Release | $3.48 $3.56 | ▲ +2.30% | ▼ −4.00% | $2.87 (−17.67%) |
Mar 13, 2026 29w ago | Press Release | $3.36 $3.21 | ▼ −4.46% | ▼ −8.05% | $2.87 (−14.73%) |
Mar 3, 2026 30w ago | Press Release | $3.82 $3.05 | ▼ −20.16% | ▼ −15.74% | $2.87 (−25.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access